Is ENGN or EXEL more undervalued in 2026?

CirclFi compares enGene Therapeutics Inc. (ENGN) and Exelixis, Inc. (EXEL) using 13 institutional-grade valuation models. ENGN has a Quality of Company score of 4.1/10 while EXEL scores 10.0/10.

Which is a better buy — ENGN or EXEL?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do ENGN and EXEL valuations compare?

ENGN at $1.85 and EXEL at $50.48 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

ENGN vs EXEL Valuation Comparison 2026 — Intrinsic Value Analysis

ENGN

Biological Products, (No Diagnostic Substances)

enGene Therapeutics Inc.

Quality

4.1

out of 10

Value Trap

SAFE

Price

$1.85

Last close

Models

8/13

Active

EXEL

Biological Products, (No Diagnostic Substances)

Exelixis, Inc.

Quality

10.0

out of 10

Value Trap

SAFE

Price

$50.48

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	ENGN Fair Value	ENGN Upside	EXEL Fair Value	EXEL Upside
Bayesian DCF	Intrinsic	$0.54	-70.9%	$27.56	-45.4%
Earnings Power Value	Intrinsic	—	—	$29.37	-41.8%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$1.93	+4.2%	$44.27	-12.3%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for ENGN vs EXEL — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ENGN vs EXEL — Which Stock Is More Undervalued?

EXEL scores higher with a 10.0/10 quality rating vs ENGN's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing enGene Therapeutics Inc. (ENGN) and Exelixis, Inc. (EXEL) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ENGN currently trades at $1.85 with a QOC of 4.1/10, while EXEL trades at $50.48 with a QOC of 10.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).